(0403–0431) Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Saturday, November 12, 2022

1:00 PM – 3:00 PM Eastern Time

Location: Virtual Poster Hall

All of the relevant financial relationships listed for faculty have been mitigated.

Poster abstract session.

Presentations:

1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study
Abstract Poster Presenter: Yu Xue, MD, PhD – Huashan Hospital affiliated to Fudan University
1:00 PM – 3:00 PM Eastern Time

Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
Abstract Poster Presenter: Michael Nissen, MBBS, FRACP – Hôpitaux Universitaires de Genève
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Baseline BMI: A Post Hoc Analysis of Phase 2 and Phase 3 Trials
Abstract Poster Presenter: Hillary Norton, MD – Santa Fe Rheumatology
1:00 PM – 3:00 PM Eastern Time

Are the BASDAI & ASQoL Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
Abstract Poster Presenter: Sinead Maguire, MB, MRCP, BAO – Toronto Western Hospital
1:00 PM – 3:00 PM Eastern Time

Effect of Biologics in MRI/CRP Subgroups of Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Abstract Poster Presenter: Sonia Gupta, MD – University of Utah
1:00 PM – 3:00 PM Eastern Time

Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Abstract Poster Presenter: Philip Robinson, PhD, FRACP, MBChB – University of Queensland
1:00 PM – 3:00 PM Eastern Time

Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
1:00 PM – 3:00 PM Eastern Time

Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals
1:00 PM – 3:00 PM Eastern Time

Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study
Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
1:00 PM – 3:00 PM Eastern Time

Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Abstract Poster Presenter: Maureen Dubreuil, MD, MSc – Boston University School of Medicine
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Abstract Poster Presenter: Augusta Ortolan, MD – University of Padova
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
1:00 PM – 3:00 PM Eastern Time

The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis
Abstract Poster Presenter: Jean Liew, MD, MS – Boston University
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Abstract Poster Presenter: Augusta Ortolan, MD – University of Padova
1:00 PM – 3:00 PM Eastern Time

Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
Abstract Poster Presenter: Dafne Capelusnik, MD – Tel Aviv Sourasky Medical Center
1:00 PM – 3:00 PM Eastern Time

Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
Abstract Poster Presenter: Jan Brandt-Juergens, MD – rheumatologische Schwerpunktpraxis
1:00 PM – 3:00 PM Eastern Time

Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline
Abstract Poster Presenter: Walter P. Maksymowych, MD – University of Alberta
1:00 PM – 3:00 PM Eastern Time

What Does It Mean - A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain
Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
1:00 PM – 3:00 PM Eastern Time

Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort
Abstract Poster Presenter: Semih Gülle, MD – Dokuz Eylul University School of Medicine
1:00 PM – 3:00 PM Eastern Time

Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study
Abstract Poster Presenter: Ana Sofia Pinto, MD – Local Health Unit of Guarda, Portugal
1:00 PM – 3:00 PM Eastern Time

The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
Abstract Poster Presenter: Semih Gülle, MD – Dokuz Eylul University School of Medicine
1:00 PM – 3:00 PM Eastern Time

Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
Abstract Poster Presenter: Mohamed-Eslam Mohamed, PhD – AbbVie
1:00 PM – 3:00 PM Eastern Time

The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
Abstract Poster Presenter: Adela Castro, MD – Hamilton Physician Group-Specialty Care
1:00 PM – 3:00 PM Eastern Time

Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
Abstract Poster Presenter: Lianne S. Gensler, MD – University of California San Francisco
1:00 PM – 3:00 PM Eastern Time

Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
Abstract Poster Presenter: Devika Dua, MD – University Hospitals Coventry and Warwickshire
1:00 PM – 3:00 PM Eastern Time

No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Abstract Poster Presenter: Mark Siderius, BSc, MSc – University Medical Centre Groningen
1:00 PM – 3:00 PM Eastern Time

The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Abstract Poster Presenter: Mark Siderius, BSc, MSc – University Medical Centre Groningen
1:00 PM – 3:00 PM Eastern Time

Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Abstract Poster Presenter: Ana Lúcia Martins Fernandes, MD – Centro Hospitalar Universitário do Algarve